Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019-03-01
Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
Related Questions
The NCCN guidelines regard MET exon 14 skip mutation as an emerging biomarker but no formal recommendation to start crizotinib. If high P...
New comment by Medical Oncologist at University of Michigan Medical School ( November 4, 2019)
See point #3 in my original answer. EGFR, ALK, and ROS1 mutations occur almost exclusively in non-smokers or long-time quitters, whereas BRAF and MET occur in a more mixed pop...